Amgen Inc.
๋กฑ

๐Ÿ”ฌ๐Ÿ’Š Amgen Innovations & Strategic Moves ๐Ÿš€

152
๐ŸŒŸ Lumakras Breakthrough:
Amgen (AMGN) pioneers cancer treatment with Lumakras, the first medication targeting a mutation found in approximately 13% of lung cancer patients.

๐Ÿ’ฐ Strategic Acquisition:
Amgen acquires Horizon Therapeutics for a substantial $28 billion in cash.
Incorporates Tepezza, an FDA-approved medicine for thyroid eye disease, into Amgen's product portfolio.

๐Ÿ“ˆ Market Outlook:
Bullish stance on AMGN suggests support levels above $260.00-$265.00.
Anticipated upside target in the range of $360.00-$365.00.

Exciting developments in biotech and strategic expansion for Amgen! ๐ŸŒ๐Ÿ’‰

#AmgenInnovation #Biotech #StockMarket ๐Ÿ“ฐ๐Ÿ“Š

๋ฉด์ฑ…์‚ฌํ•ญ

ํ•ด๋‹น ์ •๋ณด์™€ ๊ฒŒ์‹œ๋ฌผ์€ ๊ธˆ์œต, ํˆฌ์ž, ํŠธ๋ ˆ์ด๋”ฉ ๋˜๋Š” ๊ธฐํƒ€ ์œ ํ˜•์˜ ์กฐ์–ธ์ด๋‚˜ ๊ถŒ์žฅ ์‚ฌํ•ญ์œผ๋กœ ๊ฐ„์ฃผ๋˜์ง€ ์•Š์œผ๋ฉฐ, ํŠธ๋ ˆ์ด๋”ฉ๋ทฐ์—์„œ ์ œ๊ณตํ•˜๊ฑฐ๋‚˜ ๋ณด์ฆํ•˜๋Š” ๊ฒƒ์ด ์•„๋‹™๋‹ˆ๋‹ค. ์ž์„ธํ•œ ๋‚ด์šฉ์€ ์ด์šฉ ์•ฝ๊ด€์„ ์ฐธ์กฐํ•˜์„ธ์š”.